Genmab — September 2024

[Bulder]

Yes, hexabody cd38 = erzotabart. Man ændrede måden at navngive antistoffer på i 2021. The revised system was approved and adopted by the WHO at the 73rd INN Consultation held in October 2021, and the radical decision was made to discontinue the use of the well-known stem -mab in naming new antibody-based drugs and going forward, to replace it with four new stems: -tug, -bart, -mig, and -ment.

[Bulder]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/

[Bulder]

Så i stedet for erzotaMAB, kom hex38 til at hedde erzotaBART.

[Bulder]

Kan være vi her i tjatten skal gå over til det nye navn. Eller bare “erzo” svarende til “dara”

[Solsen]

Lyder gangbart

[Solsen]

Korrekt at testen er dara vs erzo.

[bikube]

JnJ releases encouraging data on Talvey combination therapies, siger S A.

[Helge_LarsenPI-redaktør]

Godmorgen.

[E_L]

DARZALEX (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned https://www.globenewswire.com/en/news-release/2024/09/27/2954641/0/en/DARZALEX-daratumumab-subcutaneous-SC-formulation-based-quadruplet-regimen-significantly-improves-minimal-residual-disease-negativity-for-newly-diagnosed-multiple-myeloma-patients-f.html

[E_L]

IMS 2024 – Darzalex fights back against Sarclisa https://www.oncologypipeline.com/apexonco/ims-2024-darzalex-fights-back-against-sarclisa

[Solsen]

Carvykti med gode 3 års data i second line https://finance.yahoo.com/news/carvykti-first-only-cell-therapy-203000097.html

[Solsen]

Vi skal nok huske de ca 60% MRD negative, når vi ser erzo data.

[Solsen]

Tillige mange bivirkninger grade 3/4

[E_L]

After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data https://www.fiercepharma.com/pharma/after-sanofis-first-line-myeloma-nod-jj-strikes-back-new-tranche-darzalex-data

[E_L]

Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art

Therapeutic Advances in Medical Oncology https://journals.sagepub.com/doi/10.1177/17588359241277647

[gentogen]

BI predicts Darzalex sales will hit $14.7 billion by 2030.

[gentogen]

BI’s belief Darzalex may fail to hit the heights anticipated by other analysts reflects the assumption that Inflation Reduction Act price cut for Darzalex in 2029 will also impact the newer subcutaneous formulation Darzalex Faspro.

[gentogen]

Just a moment...

(www.fiercepharma.com)

[gentogen]

The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost $10 billion on last year,

[Bulder]

Gentogen 9:33: Netop Winkels pointe, når han mener, at IRA kan motivere jnj til at opte in på erzo.